- Mydecine has filed a technology patent application that allows for the creation of nanoemulsion-empowered formulations to improve, stabilize, and increase the bioavailability of ingredients
- The company aims to use the nanoemulsion technology to enhance the bioavailability and optimize the delivery of compounds that are inspired by traditional ingredients
- In September, Mydecine filed its final patent application for MYCO-003, one of its lead drug candidates for enhanced treatment of anxiety and post-traumatic stress disorder
- MYCOF is steadily strengthening its IP portfolio as it seeks to reimagine the treatment of mental health and addiction
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), an emerging biotechnology and digital company dedicated to efficiently developing first- and second-generation novel therapeutics to treat PTSD, addiction, and other mental health disorders, has achieved a significant milestone for its drug development pipeline.
The Denver-based company recently filed a technology patent application that will cover as well as allow for the creation of formulations that use nanoemulsion technology to improve, stabilize, increase bioavailability, and make repeatable properties of ingredients from…
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at http://ibn.fm/MYCOF
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.